November - 2014
| Previous Past Months | Showing Journal 12 of 12 |
Cost-effectiveness of Dalteparin vs Unfractionated Heparin for the Prevention of Venous Thromboembolism in Critically Ill PatientsRobert A. Fowler, Nicole Mittmann, William Geerts, et al for the Canadian Critical Care Trials Group and the Australia and New Zealand Intensive Care Society Clinical Trials Group JAMA, 2014, online November 01, 2014. This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
November |
Previous Comments
No Comments yet.
Comment
The PROTECT trial compared the effectiveness of the 2 most common thrombo-prophylaxis pharmocoprevention strategies, low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH). They reported no difference in the primary end point of leg deep-vein thrombosis (DVT)...